Perivascular Arrest of CD8+ T Cells Is a Signature of Experimental Cerebral MalariaAntitrypanosomal Lead Discovery: Identification of a Ligand-Efficient Inhibitor of Trypanosoma cruzi CYP51 and Parasite GrowthIdentification of three classes of heteroaromatic compounds with activity against intracellular Trypanosoma cruzi by chemical library screeningThe susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposingActivity in vivo of anti-Trypanosoma cruzi compounds selected from a high throughput screeningHigh throughput screening for anti-Trypanosoma cruzi drug discoveryAutomated high-content assay for compounds selectively toxic to Trypanosoma cruzi in a myoblastic cell lineAngiotensin II Moderately Decreases Plasmodium Infection and Experimental Cerebral Malaria in MiceReplication attempt: "Effect of BMAP-28 antimicrobial peptides on Leishmania major promastigote and amastigote growth: role of leishmanolysin in parasite survival".A high-efficiency microfluidic device for size-selective trapping and sorting.New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource.Interactions between dendritic cells and CD4+ T cells during Plasmodium infection.Migration of Plasmodium sporozoites through cells before infection.Plasmodium-induced inflammation by uric acidAdenylyl cyclase alpha and cAMP signaling mediate Plasmodium sporozoite apical regulated exocytosis and hepatocyte infection.New pieces for the malaria liver stage puzzle: where will they fit?Uric acid is a mediator of the Plasmodium falciparum-induced inflammatory response.Diversity-oriented synthesis yields a new drug lead for treatment of chagas diseaseA surprising role for uric acid: the inflammatory malaria response.Dual effect of Plasmodium-infected erythrocytes on dendritic cell maturation.Quantification of IgM molecular response by droplet digital PCR as a potential tool for the early diagnosis of sepsis.A putative kinase-related protein (PKRP) from Plasmodium berghei mediates infection in the midgut and salivary glands of the mosquitoIdentification of small-molecule inhibitors of Trypansoma cruzi replication.Color capable sub-pixel resolving optofluidic microscope and its application to blood cell imaging for malaria diagnosisInhibition of Plasmodium sporozoites infection by targeting the host cell.Malaria and hypertension. Another co-evolutionary adaptation?Invasion of mammalian host cells by Plasmodium sporozoites.A potential role for plasma uric acid in the endothelial pathology of Plasmodium falciparum malaria.Plasmodium falciparum-derived uric acid precipitates induce maturation of dendritic cells.Daily Plasmodium yoelii infective mosquito bites do not generate protection or suppress previous immunity against the liver stage.EVALUATION OF AROMATIC 6-SUBSTITUTED THIENOPYRIMIDINES AS SCAFFOLDS AGAINST PARASITES THAT CAUSE TRYPANOSOMIASIS, LEISHMANIASIS, AND MALARIA.Small-molecule xenomycins inhibit all stages of the Plasmodium life cycleImaging and identification of waterborne parasites using a chip-scale microscope.Plasmodium yoelii yoelii 17XNL constitutively expressing GFP throughout the life cycle.Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery.Targeting Plasmodium host cells: survival within hepatocytes.Migration through host cells: the first steps of Plasmodium sporozoites in the mammalian host.Antiparasitic Lead Discovery: Toward Optimization of a Chemotype with Activity Against Multiple Protozoan Parasites.Chemical attenuation of Plasmodium berghei sporozoites induces sterile immunity in mice.The silent path to thousands of merozoites: the Plasmodium liver stage.
P50
Q27316972-6C1A6F7C-EB1B-44E9-B635-1F4BCE67946EQ27676649-E27AE8FA-08E2-471C-91E3-71D594CF0154Q28474784-3925D984-5BB2-49B5-96BC-E2B6F0C0D63AQ28476644-3ACFE3F7-E675-4820-A244-D9151005225BQ28476774-22A95CF8-8F30-4D80-95C2-89E80DFFAB6DQ28542489-170885F1-E684-4FEB-9D44-85FE10CC3666Q28543069-2624EFC7-041B-47FA-BE72-B503C9ACEA55Q28548078-23D7EFE2-5C7C-4565-ADF6-B56A48B919C5Q28649604-3B6CBFE1-1186-43BB-B168-7277867CFBE7Q30406557-8BB87A59-67E6-407D-A93B-CCA5C3963EECQ30417002-946D7634-8A14-4D65-9FC7-801C650B5EC0Q30482250-9AA7D81E-0325-4ECB-A2E8-366927B54ED7Q31805399-14F071C7-0C48-418B-9EDF-92FB07C09EC6Q33325912-23EC94CC-4A3F-443E-83E5-679B6ECED87EQ33326989-6B3ED558-E562-4FCD-94DB-E629A0CB5019Q33345272-91E937AD-338A-45C9-9A8B-2A8995364504Q33432736-2F96CE6D-0B37-4542-8AA6-22AF2FDAE5FEQ33636200-B97779A8-C823-4E36-978D-C398EF38DCD0Q33684119-E3726085-869B-42C0-A90F-34A8ABBDDB5AQ33741807-7FE18AD9-468A-4E08-A2F0-E59D42FD30E7Q33822009-97ADA20D-CF9A-494B-A2FA-28123B6F8FF2Q33872598-BE8C87FE-D828-4B5B-B2D8-485E9E503EDDQ34054192-FD5188D4-D5C8-4D59-9F47-A5D099993B0EQ34056040-1B761A30-8709-45B0-857A-37ED8DDCFC49Q34076531-701B81A9-D424-4A91-A04C-40D51E41F168Q34127049-E4D26324-CCE3-40A6-8B7C-D736D44E4638Q34522332-12AED75B-8BCF-4FC4-AE88-03A0F62F288CQ34563150-41417E09-2842-4563-A85B-F858A05A5297Q34584339-A5AA2552-CD58-459E-816C-5BD1AA7C3032Q35009202-E67E7D88-5B4B-43FA-831A-EC1FF69F702DQ35072529-EE2DE600-3C3C-44EC-9181-3E7951579B60Q35076935-B5842DCD-9CFD-4CCE-9831-522309B52239Q35107941-72239352-5115-4538-A025-E7D56D00D2B9Q35606758-B046D3F9-39B2-41AE-B150-B4573F1ED270Q35891268-B0CCCE5F-672D-4DB5-82A6-CDA36B04AD9BQ35908980-62A38CF1-E250-44CF-BA17-5FDFF306D35FQ35939872-F2D237DA-CFB6-4478-9924-CD922CD571BAQ36321435-D6521F81-723B-4EB7-B9DB-10FF82D5FA4CQ36483596-BF1B7085-50AB-408F-84D1-611D940B9107Q36623691-2C9A8F94-2DF1-4B34-B1B4-42E6476EC41A
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ana Rodriguez
@ast
Ana Rodriguez
@en
Ana Rodriguez
@es
type
label
Ana Rodriguez
@ast
Ana Rodriguez
@en
Ana Rodriguez
@es
altLabel
Ana Maria Rodriguez Fernandez
@en
prefLabel
Ana Rodriguez
@ast
Ana Rodriguez
@en
Ana Rodriguez
@es
P106
P21
P31
P496
0000-0002-0060-3405